Psyence Biomedical Ltd. Common Shares (PBM) is a publicly traded Healthcare sector company. As of May 21, 2026, PBM trades at $4.00 with a market cap of $10.57M and a P/E ratio of 0.00. PBM moved +2.56% today. Year to date, PBM is -19.70%; over the trailing twelve months it is -89.32%. Its 52-week range spans $1.92 to $515.56. Rallies surfaces PBM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Psyence BioMed Schedules U.S. Outreach on GMP Ibogaine Manufacturing from African Facility: Psyence BioMed’s CEO Jody Aufrichtig will travel to the U.S. to meet researchers, institutions, industry leaders and government stakeholders on regulatory pathways for GMP-compliant ibogaine production. The company’s investment in a Southern Africa PsyLabs facility provides cultivation, extraction, purification and manufacturing capabilities to supply pharmaceutical-grade ibogaine for clinical research.
| Metric | Value |
|---|---|
| Price | $4.00 |
| Market Cap | $10.57M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $515.56 |
| 52-Week Low | $1.92 |
| Volume | 1.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
PBM analyst coverage data. Average price target: $0.00.